Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation

Learn more about:
Related Clinical Trial
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation Prospective Multicenter Evaluation of a New Short-access-cholangioscope for Biliary Duct Strictures and Gall Stones Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease A Trial of Taurine Supplementation in Parenteral Nutrition 1 Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease Gabapentin to Treat Itch in Patients With Liver Disease Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat Compassionate Use of Omegaven Omegaven® as Parenteral Nutrition A Randomized Controlled Trial (RCT) of Carbon Dioxide Versus Air Insufflation During Endoscopic Retrograde Cholangiopancreatography (ERCP) Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers Compassionate Use of Omegaven IV Fat Emulsion SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia Omegaven as Alternative Parenteral Fat Nutrition Minimization of IntraLipid Versus Omegaven Compassionate Use of Omegaven IV Fat Emulsion Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders Fibrates in Pediatric Cholestasis Cholestasis Prevention: Efficacy of IV Fish Oil Preventing Cholestasis Using SMOFLipid® Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region

Brief Title

Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation


Brief Summary

      This study is designed to investigate the possible beneficial effects of UDCA on liver graft
      recovery early after adult liver transplantation.
    



Study Type

Interventional


Primary Outcome

Serum liver tests

Secondary Outcome

 Postoperative complications

Condition

Liver Transplantation

Intervention

ursodeoxycholic acid

Study Arms / Comparison Groups

 ursodeoxycholic acid
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

112

Start Date

May 2005

Completion Date

January 2009

Primary Completion Date

April 2008

Eligibility Criteria

        Inclusion Criteria:

          -  All liver transplant patients in our center between May 2005 and April 2008 were
             potentially eligible for enrollment

        Exclusion Criteria:

          -  Age less than 18 years

          -  Treatment with UDCA within one month before operation

          -  Inability to provide written informed consent prior to study entry

          -  Non-liver organ(s) failure prior to entry
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Zhi-Hai Peng, MD, , 

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT01073202

Organization ID

SFPH05B41



Study Sponsor

Shanghai Jiao Tong University School of Medicine


Study Sponsor

Zhi-Hai Peng, MD, Study Chair, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine


Verification Date

December 2009